Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 3,096 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,096 shares of the company’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $50.13, for a total value of $155,202.48. Following the completion of the transaction, the director now owns 279,787 shares of the company’s stock, valued at $14,025,722.31. The trade was a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Pro-Dex Price Performance

PDEX opened at $48.23 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The stock’s 50 day simple moving average is $40.21 and its 200 day simple moving average is $39.99. The firm has a market cap of $157.28 million, a price-to-earnings ratio of 24.00 and a beta of 0.68. Pro-Dex, Inc. has a 1 year low of $16.84 and a 1 year high of $59.60.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, analysts predict that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Hedge Funds Weigh In On Pro-Dex

Several hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp grew its stake in shares of Pro-Dex by 14.1% in the fourth quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock worth $1,672,000 after purchasing an additional 4,426 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after buying an additional 2,296 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares during the last quarter. EAM Investors LLC purchased a new position in shares of Pro-Dex during the fourth quarter valued at approximately $1,047,000. Finally, O Shaughnessy Asset Management LLC bought a new position in shares of Pro-Dex during the fourth quarter valued at approximately $995,000. 15.28% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.